FINWIRES · TerminalLIVE
FINWIRES

ニューテックグループ傘下企業がニューソフトの子会社と高齢者介護事業の合弁会社を設立へ

-- ニューテックグループ(香港証券取引所:9616)傘下のダリアン・ニューソフト・ルイシン・ヘルステクノロジーは、上海ニューソフト・データテクノロジーと合弁会社「上海ニューソフト・ルイシン・ヘルステクノロジー」を設立する契約を締結した。香港証券取引所への同日提出書類で明らかになった。 合弁会社の登録資本金1億3000万元のうち、ダリアン・ニューソフト・ルイシン・ヘルステクノロジーが1億400万元、上海ニューソフト・データテクノロジーが2600万元を出資し、それぞれ80%と20%の株式を保有する。 上海ニューソフト・ルイシン・ヘルステクノロジーは、都市規模のスマート高齢者ケアプラットフォームと製品の普及促進を専門とする持株会社であり、効果的な高齢者ケアエコシステムの構築を目指す。 大連ニューソフト瑞信健康科技は、2025年6月以降、既に他の4つの合弁会社設立に関する契約を締結している。 上海ニューソフトデータテクノロジーは、ニューソフトコーポレーション(上海証券取引所:600718)の子会社である。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703